Dr Varsha Tembe

Postdoctoral Scientist
Medicine, Westmead Clinical School


Map

Selected grants

2004

  • Regulation of BARD1 subcellular localisation and function in breast cancer; Tembe V; University of Sydney/Scholarship Agreement.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Jayawardana, K., Schramm, S., Tembe, V., Mueller, S., Thompson, J., Scolyer, R., Mann, G., Yang, J. (2016). Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. Journal of Investigative Dermatology, 136(1), 245-254. [More Information]
  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Long, G., Carlino, M., et al (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. [More Information]
  • Tembe, V., Schramm, S., Stark, M., Patrick, E., Jayaswal, V., Tang, Y., Barbour, A., Hayward, N., Thompson, J., Scolyer, R., Yang, J., Mann, G. (2015). microRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. Pigment Cell & Melanoma Research, 28(3), 254-226. [More Information]
  • Tembe, V., Martino-Echarri, E., Marzec, K., Mok, M., Brodie, K., Mills, K., Lei, Y., deFazio, A., Rizos, H., Kettle, E., Henderson, B., et al (2015). The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function. Cellular Signalling, 27(9), 1763-1771. [More Information]
  • Wilmott, J., Field, M., Johansson, P., Kakavand, H., Shang, P., De Paoli-Iseppi, R., Vilain, R., Pupo, G., Tembe, V., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., et al (2015). Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 47(7), 683-693. [More Information]
  • Long, G., Fung, C., Menzies, A., Pupo, G., Carlino, M., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J., Saw, R., Howle, J., Scolyer, R., Kefford, R., Rizos, H., et al (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 5, 1-9. [More Information]
  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell & Melanoma Research, 26(4), 499-508. [More Information]
  • Dutton-Regester, K., Kakavand, H., Aoude, L., Stark, M., Gartside, M., Johansson, P., O'Connor, L., Lanagan, C., Tembe, V., Pupo, G., Haydu, L., Mann, G., Thompson, J., Scolyer, R., et al (2013). Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell & Melanoma Research, 26(6), 852-860. [More Information]
  • Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L., Tembe, V., Pupo, G., Lanagan, C., Carter, C., O'Connor, L., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 11(4), 888-897. [More Information]
  • Dutton-Regester, K., Aoude, L., Nancarrow, D., Stark, M., O'Connor, L., Lanagan, C., Pupo, G., Tembe, V., Carter, C., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). Identification of TFG (TRK-Fused Gene) as a Putative Metastatic Melanoma Tumor Suppressor Gene. Genes Chromosomes and Cancer, 51(5), 452-461. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Anforth, R., Tembe, V., Blumetti, T., Fernandez Penas, P. (2012). Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking braf inhibitors. Pigment Cell & Melanoma Research, 25(5), 569-572. [More Information]
  • Tembe, V., Henderson, B. (2007). BARD1 Translocation to Mitochondria Correlates with Bax Oligomerization, Loss of Mitochondrial Membrane Potential, and Apoptosis. Journal of Biological Chemistry, 282(28), 20513-20522. [More Information]
  • Tembe, V., Henderson, B. (2007). Protein trafficking in response to DNA damage. Cellular Signalling, 19(6), 1113-1120. [More Information]
  • Schüchner, S., Tembe, V., Rodriguez, J., Henderson, B. (2005). Nuclear targeting and cell cycle regulatory function of human BARD1. Journal of Biological Chemistry, 280(10), 8855-8861. [More Information]
  • Daniel, A., Wu, Z., Darmanian, A., Malafiej, P., Tembe, V., Peters, G., Kennedy, C., Ades, L. (2004). Issues Arising From The Prenatal Diagnosis Of Some Rare Trisomy Mosaics--The Importance Of Cryptic Fetal Mosaicism. Prenatal diagnosis, 24(7), 524-536. [More Information]

2016

  • Jayawardana, K., Schramm, S., Tembe, V., Mueller, S., Thompson, J., Scolyer, R., Mann, G., Yang, J. (2016). Identification, Review, and Systematic Cross-Validation of microRNA Prognostic Signatures in Metastatic Melanoma. Journal of Investigative Dermatology, 136(1), 245-254. [More Information]

2015

  • Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Long, G., Carlino, M., et al (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. [More Information]
  • Tembe, V., Schramm, S., Stark, M., Patrick, E., Jayaswal, V., Tang, Y., Barbour, A., Hayward, N., Thompson, J., Scolyer, R., Yang, J., Mann, G. (2015). microRNA and mRNA expression profiling in metastatic melanoma reveal associations with BRAF mutation and patient prognosis. Pigment Cell & Melanoma Research, 28(3), 254-226. [More Information]
  • Tembe, V., Martino-Echarri, E., Marzec, K., Mok, M., Brodie, K., Mills, K., Lei, Y., deFazio, A., Rizos, H., Kettle, E., Henderson, B., et al (2015). The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function. Cellular Signalling, 27(9), 1763-1771. [More Information]
  • Wilmott, J., Field, M., Johansson, P., Kakavand, H., Shang, P., De Paoli-Iseppi, R., Vilain, R., Pupo, G., Tembe, V., Jakrot, V., Thompson, J., Mann, G., Scolyer, R., et al (2015). Tumour procurement, DNA extraction, coverage analysis and optimisation of mutation-detection algorithms for human melanoma genomes. Pathology, 47(7), 683-693. [More Information]

2014

  • Long, G., Fung, C., Menzies, A., Pupo, G., Carlino, M., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J., Saw, R., Howle, J., Scolyer, R., Kefford, R., Rizos, H., et al (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 5, 1-9. [More Information]

2013

  • Long, G., Wilmott, J., Haydu, L., Tembe, V., Sharma, R., Rizos, H., Thompson, J., Howle, J., Scolyer, R., Kefford, R. (2013). Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment and on progression. Pigment Cell & Melanoma Research, 26(4), 499-508. [More Information]
  • Dutton-Regester, K., Kakavand, H., Aoude, L., Stark, M., Gartside, M., Johansson, P., O'Connor, L., Lanagan, C., Tembe, V., Pupo, G., Haydu, L., Mann, G., Thompson, J., Scolyer, R., et al (2013). Melanomas of unknown primary have a mutation profile consistent with cutaneous sun-exposed melanoma. Pigment Cell & Melanoma Research, 26(6), 852-860. [More Information]

2012

  • Dutton-Regester, K., Irwin, D., Hunt, P., Aoude, L., Tembe, V., Pupo, G., Lanagan, C., Carter, C., O'Connor, L., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). A High-Throughput Panel for Identifying Clinically Relevant Mutation Profiles in Melanoma. Molecular Cancer Therapeutics, 11(4), 888-897. [More Information]
  • Dutton-Regester, K., Aoude, L., Nancarrow, D., Stark, M., O'Connor, L., Lanagan, C., Pupo, G., Tembe, V., Carter, C., O'Rourke, M., Scolyer, R., Mann, G., et al (2012). Identification of TFG (TRK-Fused Gene) as a Putative Metastatic Melanoma Tumor Suppressor Gene. Genes Chromosomes and Cancer, 51(5), 452-461. [More Information]
  • Wilmott, J., Tembe, V., Howle, J., Sharma, R., Thompson, J., Rizos, H., Lo, R., Kefford, R., Scolyer, R., Long, G. (2012). Intratumoral Molecular Heterogeneity in a BRAF-Mutant, BRAF Inhibitor-Resistant Melanoma: A Case Illustrating the Challenges for Personalized Medicine. Molecular Cancer Therapeutics, 11(12), 2704-2708. [More Information]
  • Anforth, R., Tembe, V., Blumetti, T., Fernandez Penas, P. (2012). Mutational analysis of cutaneous squamous cell carcinomas and verrucal keratosis in patients taking braf inhibitors. Pigment Cell & Melanoma Research, 25(5), 569-572. [More Information]

2007

  • Tembe, V., Henderson, B. (2007). BARD1 Translocation to Mitochondria Correlates with Bax Oligomerization, Loss of Mitochondrial Membrane Potential, and Apoptosis. Journal of Biological Chemistry, 282(28), 20513-20522. [More Information]
  • Tembe, V., Henderson, B. (2007). Protein trafficking in response to DNA damage. Cellular Signalling, 19(6), 1113-1120. [More Information]

2005

  • Schüchner, S., Tembe, V., Rodriguez, J., Henderson, B. (2005). Nuclear targeting and cell cycle regulatory function of human BARD1. Journal of Biological Chemistry, 280(10), 8855-8861. [More Information]

2004

  • Daniel, A., Wu, Z., Darmanian, A., Malafiej, P., Tembe, V., Peters, G., Kennedy, C., Ades, L. (2004). Issues Arising From The Prenatal Diagnosis Of Some Rare Trisomy Mosaics--The Importance Of Cryptic Fetal Mosaicism. Prenatal diagnosis, 24(7), 524-536. [More Information]

To update your profile click here. For support on your academic profile contact .